STOCK TITAN

[Form 4] Aquestive Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Aquestive Therapeutics (AQST) reported an insider transaction on a Form 4. An officer sold 10,000 shares of common stock at $7 on 10/15/2025, reported with transaction code S.

The filing states the sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan. Following the transaction, the reporting person beneficially owns 268,323 shares, held directly. The officer’s title is SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) ha riferito una operazione insider su un modulo 4. Un dirigente ha venduto 10.000 azioni ordinarie a 7 dollari il 15/10/2025, riportata con il codice di transazione S. La presentazione indica che le vendite sono state effettuate ai sensi di un piano di trading Rule 10b5-1 già adottato. Dopo la transazione, la persona che ha presentato la dichiarazione possiede 268.323 azioni, detenute direttamente. Il titolo dell’ufficiale è SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) informó una operación de insider en un Formulario 4. Un funcionario vendió 10.000 acciones de acciones comunes a 7 dólares el 15/10/2025, reportada con el código de transacción S. La presentación indica que las ventas se efectuaron conforme a un plan de negociación Rule 10b5-1 previamente adoptado. Tras la transacción, la persona que informa posee 268.323 acciones, en forma directa. El cargo del funcionario es SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) 는 Form 4에 대한 내부자 거래를 보고했습니다. 한 임원이 10,000주의 보통주를 $72025-10-15에 매도했고 거래 코드 S로 보고되었습니다. 공시에 따르면 매매는 미리 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다. 거래 후 보고자는 268,323주직접 보유하고 있습니다. 임원의 직함은 SVP IT, HR, & Communications입니다.

Aquestive Therapeutics (AQST) a signalé une opération d'initié sur un formulaire 4. Un dirigeant a vendu 10 000 actions ordinaires à 7 dollars le 15/10/2025, signalée avec le code de transaction S. Le dossier indique que les ventes ont été effectuées conformément à un plan de négociation Rule 10b5-1 préalablement adopté. Suite à la transaction, la personne déclarante possède 268 323 actions, directement détenues. Le titre du dirigeant est SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) meldete eine Insider-Transaktion auf einem Formular 4. Ein Beamter verkaufte 10.000 Aktien der Stammaktie zu 7 Dollar am 15.10.2025, gemeldet mit dem Transaktionscode S. Die Einreichung erklärt, dass die Verkäufe gemäß einem zuvor angenommenen Rule 10b5-1-Handelsplan durchgeführt wurden. Nach der Transaktion besitzt die meldende Person 268.323 Aktien, direkt gehalten. Der Titel des Beamten lautet SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) أبلغت عن عملية داخلية على نموذج 4. باع ضابط 10,000 سهم من الأسهم العادية بسعر 7 دولارات في 15/10/2025، مُبلغ عنها مع رمز المعاملة S. تفيد الإحاطة أن المبيعات تمت وفقاً لـ خطة تداول Rule 10b5-1 التي تم اعتمادها سابقاً. عقب المعاملة، يمتلك الشخص المبلغ 268,323 سهم، بشكل مباشر. عنوان الضابط هو SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) 在 Form 4 上报告了一起内幕交易。 一名官员以 7 美元价格出售了 10,000 股 普通股,时间为 2025/10/15,交易代码为 S。披露显示,销售是根据先前采用的 Rule 10b5-1 交易计划 实施。交易后,申报人实际拥有 268,323 股直接持有。 该官员的头衔是 SVP IT, HR, & Communications

Positive
  • None.
Negative
  • None.

Aquestive Therapeutics (AQST) ha riferito una operazione insider su un modulo 4. Un dirigente ha venduto 10.000 azioni ordinarie a 7 dollari il 15/10/2025, riportata con il codice di transazione S. La presentazione indica che le vendite sono state effettuate ai sensi di un piano di trading Rule 10b5-1 già adottato. Dopo la transazione, la persona che ha presentato la dichiarazione possiede 268.323 azioni, detenute direttamente. Il titolo dell’ufficiale è SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) informó una operación de insider en un Formulario 4. Un funcionario vendió 10.000 acciones de acciones comunes a 7 dólares el 15/10/2025, reportada con el código de transacción S. La presentación indica que las ventas se efectuaron conforme a un plan de negociación Rule 10b5-1 previamente adoptado. Tras la transacción, la persona que informa posee 268.323 acciones, en forma directa. El cargo del funcionario es SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) 는 Form 4에 대한 내부자 거래를 보고했습니다. 한 임원이 10,000주의 보통주를 $72025-10-15에 매도했고 거래 코드 S로 보고되었습니다. 공시에 따르면 매매는 미리 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다. 거래 후 보고자는 268,323주직접 보유하고 있습니다. 임원의 직함은 SVP IT, HR, & Communications입니다.

Aquestive Therapeutics (AQST) a signalé une opération d'initié sur un formulaire 4. Un dirigeant a vendu 10 000 actions ordinaires à 7 dollars le 15/10/2025, signalée avec le code de transaction S. Le dossier indique que les ventes ont été effectuées conformément à un plan de négociation Rule 10b5-1 préalablement adopté. Suite à la transaction, la personne déclarante possède 268 323 actions, directement détenues. Le titre du dirigeant est SVP IT, HR, & Communications.

Aquestive Therapeutics (AQST) meldete eine Insider-Transaktion auf einem Formular 4. Ein Beamter verkaufte 10.000 Aktien der Stammaktie zu 7 Dollar am 15.10.2025, gemeldet mit dem Transaktionscode S. Die Einreichung erklärt, dass die Verkäufe gemäß einem zuvor angenommenen Rule 10b5-1-Handelsplan durchgeführt wurden. Nach der Transaktion besitzt die meldende Person 268.323 Aktien, direkt gehalten. Der Titel des Beamten lautet SVP IT, HR, & Communications.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Boyd Peter E.

(Last) (First) (Middle)
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE

(Street)
WARREN NJ 07059

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 S(1) 10,000 D $7 268,323 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
Remarks:
SVP IT, HR, & Communications
/s/ Lori Braender, as Attorney-In-Fact 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did AQST disclose on this Form 4?

An officer sold 10,000 shares of common stock at $7 on 10/15/2025.

Was the AQST trade under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a previously adopted Rule 10b5-1 trading plan.

How many AQST shares does the insider own after the sale?

The reporting person beneficially owns 268,323 shares directly after the transaction.

What was the transaction code on the AQST Form 4?

The transaction used code S, indicating a sale.

Who is the AQST insider named in the filing?

The reporting person is an officer with the title SVP IT, HR, & Communications.

What is the price per share for the AQST insider sale?

The reported sale price was $7 per share.
Aquestive Therapeutics

NASDAQ:AQST

AQST Rankings

AQST Latest News

AQST Latest SEC Filings

AQST Stock Data

848.03M
110.89M
4.15%
42.85%
7.67%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
WARREN